Ondine Biomedical (LON:OBI) Shares Down 2.4% – Should You Sell?

Ondine Biomedical Inc. (LON:OBI)’s share price dropped 2.4% during mid-day trading on Friday. The stock traded as low as C$9.50 and last traded at C$10.00. 539,511 shares were traded during trading, a decline of 8% from the average session volume of 589,536 shares. The stock had previously closed at C$10.25.

Ondine Biomedical Price Performance

The company has a market capitalization of C$5.20 billion, a PE ratio of -1.67 and a beta of 0.30. The company has a quick ratio of 8.26, a current ratio of 0.65 and a debt-to-equity ratio of -8.65. The firm’s 50-day moving average is C$10.71 and its 200-day moving average is C$12.63.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.